- About Us
- Nano-Social Network
- Nano Consulting
- My Account
A new report from Cientifica Ltd., "The Nanoparticle Drug Delivery Market", identifies who is positioned to be the "winners" and "losers" in the drug delivery market as new nanoparticles and nanostructured delivery techniques begin replacing existing polymer therapeutics that currently dominate the market.
The report, available at http://www.cientifica.com , projects that the total market for nanotechnology-enabled drug delivery will rise to $26 billion by 2012 from its current size of $3.39 billion, representing a compound annual growth rate of 37%.
But this is just the beginning; the market could steeply rise after 2012, reaching potentially $220 billion by 2015 for these nano-enabled compounds.
With such enormous growth anticipated, the 300-page report examines over 60 different companies, including 38 drug formulation companies and 23 drug delivery companies, analyzing where they are in their product pipeline, the available market, and the value that their products add to drug delivery.
With 58 case studies of nanoparticle drug delivery platforms and technologies, it becomes possible both for investors and companies in the pharmaceutical industry to understand how nanotechnologies will impact the drug delivery market and the companies in the best position to exploit this growth.
Nanotechnologies have already begun to change the scale and methods of drug delivery and hold huge potential for future developments in this area. New formulations and routes for drug delivery have the potential to broaden the therapeutic potential of administered treatments by allowing the delivery of new types of medicine to previously inaccessible sites in the body. In contrast to developing completely new drug compounds, introducing upgraded formulations greatly reduces the risk, time and capital invested in new drug development.
Nanoparticle drug delivery technology can enable reformulation of existing drugs to increase product lifecycle, increase profitability, expand intellectual property estate and discourage competition during a drug's most valuable years.
Research Director Hailing Yu commented "A new value paradigm is taking shape in this market. By understanding how these nanostructured delivery techniques will shape the future of this market, investors and companies involved in the space will have a map for this new landscape."
About Cientifica Ltd.
Cientifica is the world's leading independent supplier of nanotechnology research and technology information, with activities spanning from basic research to consultancy, business intelligence and investments.
For more information, please click here
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
“Cysteine Rose” Wins 2016 Thermo Fisher Scientific Electron Microscopy Image Contest: Thermo Fisher honors Andrea Jacassi of the Italian Institute of Technology for image of cysteine crystals using focused ion beam techniques March 27th, 2017
ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX® Technology Platform: Leading-edge I-fuse™ brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017
Leti and HORIBA Scientific to Host Webinar on Ultrafast Characterization Tool: Plasma Profiling Time-of-Flight Mass Spectrometer Tool Cuts Optimization Time In Layer Deposition and Fabrication of Wide Range of Applications March 27th, 2017
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Argon is not the 'dope' for metallic hydrogen March 24th, 2017